



The Henning Løwenstein Research Award 2024

Call for applicants

The Henning Løwenstein Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy.

The winner will receive € 20,000* and will be offered a travel grant to attend the award ceremony at ALK, Hørsholm, Denmark, 1st March 2024.

Scientists are invited to apply for the Henning Løwenstein Research Award 2024.

The Henning Løwenstein Research Award 2024

To a young scientist who has shown excellence within the field of allergy

Over the last few decades allergy has increased in prevalence to become the most common chronic disease in modern societies. The causes for this sudden change are not entirely clear, although they seem to be linked to 'modern lifestyle'.

For many years doctors have advised patients to avoid allergen exposure as a means of reducing symptoms; but recent research seem to indicate that there is no simple dose-response relationship between exposure and symptoms.

Pharmacotherapy is in widespread use all over the world to treat respiratory allergic disease. Although effective in controlling symptoms, pharmacotherapy does not change the course of disease and it does not prevent increases in prevalence.

It appears that allergy immunotherapy is the only treatment to treat the cause, induce immunological tolerance and to prompt disease modification. Disease modification implies long term effect, prevention of asthma in children with allergic rhinitis and prevention of new allergies.

In ALK we believe that reinforced efforts in research on the characteristics and treatment of respiratory allergic disease will lead the way for future achievements to the benefit of people with allergies all over the world.

The Henning Løwenstein Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy. The 2024 Award includes €20,000* and a travel grant to attend the award ceremony at ALK, Hørsholm, Denmark, 1st March 2024.

* If the winner is from a country where local legislation or medicolegal regulation prevents the transfer of monetary awards from the pharmaceutical industry to healthcare professionals, and in the case that the selected winner is a healthcare professional, the award is substituted by a travel grant or an educational grant of corresponding value. The grant is managed by ALK A/S and specified payment can only be given in the form of tickets or refund of tickets for a scientific or educational purpose, which is in agreement with the medicolegal regulation in that country. Accepted purposes could be transportation to a scientific congress or educational event, registration fees, educational charges or accommodation. ALK will ensure that each purpose is in agreement with the regulation in that particular country.

Application guidelines

The Henning Løwenstein Research Award 2024

Scientists may apply for the Henning Løwenstein Research Award of €20,000*.

- Applications must be concise, max. 2 pages including essential references, and should describe previous and current research activities.
- The applicant's precise role in these activities must be clearly stated.
- The applicant's curriculum vitae must also be enclosed, max. 2 pages.
- Applicants should be early in their academic career, within 10 years of their PhD (or equivalent degree), and should not be considered an established scientist, ie head of department, professor, etc.

**Please forward the application labelled
“The Henning Løwenstein Research Award 2024” to:
ALK A/S, Bøge Allé 6-8, DK-2970 Hørsholm, Denmark,
or preferentially by e-mail to: HLAward@alk.net**

An International Scientific Board will evaluate the applications.

The members are:

Henning Løwenstein (Chairman), Denmark
Stephen Durham, United Kingdom *Stephen Till, United Kingdom*
Lars K. Poulsen, Denmark *Anne Tscopoulos, France*
Harald Renz, Germany *Margitta Worm, Germany*

Deadline for applications: 30 November 2023



Winners of the Henning Løwenstein Research Award

The Henning Løwenstein Research Award

2021: Julia Esser - von Bieren, Technical University, Munich, Germany

The ARIA-EUFOREA Henning Løwenstein Research Award

2019: Kornel Golebski, University of Amsterdam, the Netherlands

The WAO Henning Løwenstein Research Award

2015: Stefanie Eyerich, Technical University and Helmholtz Center, Munich, Germany

2013: Bianca Schaub, Ludwig-Maximilian-University, Munich, Germany

2011: Zoulfia Allakhverdi, University of Montreal, Canada, and Natalija Novak, University of Bonn, Germany

2009: Stephen J Till, Imperial College, London, United Kingdom

2007: Barbara Bohle, Medical University of Vienna, Austria

The Henning Løwenstein Research Award

2005: Omid Akbari, Harvard University, United States of America

2004: Christopher Lynn Kepley, Commonwealth University of Virginia, United States of America

2003: Erika Ganglberger, University of Vienna, Austria

2002: Miriam Fleur Moffatt, University of Oxford, United Kingdom

2001: Eckard Hamelmann, Humboldt-University of Berlin, Germany

2000: Mark Larché, Imperial College, London, United Kingdom



ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Find more information at www.alk.net.

ALK A/S
Bøge Allé 6-8
DK-2970 Hørsholm
Denmark
Tel: +45 45 74 75 76
Fax: +45 45 74 86 90
www.alk.net